ASX Announcements 2016 Home » Investors » ASX Announcements » ASX Announcements 2016 Investors ASX Announcements Corporate Governance Share Price Investor Presentations Annual Reports ASX Announcements 2016 21.12.16 - Change in substantial holding 15.12.16 - Completion of Initial CMAX Transaction 22.11.16 - Mayne Pharma Announces U.S. Launch of IDT's Temozolomide 7.11.16 - Ceasing to be a substantial holder from AEF 2.11.16 - 1st generic proprietary product shipped to US, temozolomide 28.10.16 - IDT Divests CMAX Clinical Trial Business to I'rom Group 21.10.16 - Appendix 3B 18.10.16 - Results of Meeting 12.10.16 - Director Resignation 17.10.16 - Investor Presentation, AGM 17 October 2016 7.10.16 - Receives Export Award, Health and Biotechnology 20.9.16 - Change in substantial holder from AEF 21.9.16 - Cancellation of shares 21.9.16 - Appendix 3B 16.9.16 - Notice of Annual General Meeting/Proxy Form 9.9.16 - Change of Melbourne Registry Address Notification 6.9.16 - Awarded Future Industries Manufacturing Program Grant 25.8.16 - Appendix 4G 24.7.16 - Full Year Statutory Accounts 24.7.16 - Appendix 4E 3.7.16 - Appendix 3B 6.7.16 - Cleansing Notice 6.7.16 - Appendix 3B 1.7.16 - Becoming a substantial holder 30.6.16 - Completion of private placement 28.6.16 - Trading Halt 27.6.16 - Updated Investor Presentation 8.6.16 - Ceasing to be a substantial holder 2.5.16 - CMAX - Opening of new Clinical Trial Facility 4.4.16 - Updated Investor Presentation 13.4.16 - FDA Approval for Temozolomide 30.3.16 - Manufacturing partner appointed 9.3.16 - Thiotepa - Contract Extension and Revenues 19.2.16 - Half Yearly Report and Accounts 19.2.16 - Appendix 4D 15.2.16 - Ceasing to be a substantial holder 4.1.16 - Becoming a substantial holder
